KPHMT1 Antibody

What is PKMYT1 and what cellular functions does it regulate?

PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1) acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylating the CDK1 kinase when complexed with cyclins. It predominantly mediates phosphorylation of CDK1 on Thr-14, but may also be involved in phosphorylation on Tyr-15, though this tyrosine kinase activity is less clear and might be indirect. Beyond cell cycle regulation, PKMYT1 is involved in Golgi fragmentation, suggesting a multifunctional role in cellular processes .

What applications is the PKMYT1 antibody suitable for?

Based on validated research protocols, PKMYT1 antibody (specifically ab221738) is suitable for immunocytochemistry/immunofluorescence (ICC/IF) applications with human samples. The antibody has been successfully utilized at 4 μg/ml concentration in PFA-fixed, Triton X-100 permeabilized MCF7 cells (human breast adenocarcinoma cell line), demonstrating clear visualization of PKMYT1 protein .

What are the key characteristics of commercially available PKMYT1 antibodies?

The PKMYT1 antibody referenced in research literature is a rabbit polyclonal antibody, generated using a recombinant fragment corresponding to the C-terminal region (amino acids 400 to C-terminus) of human PKMYT1 protein. This polyclonal nature provides recognition of multiple epitopes within the target region, potentially enhancing detection sensitivity in research applications .

How should samples be prepared for optimal PKMYT1 antibody staining?

For optimal immunofluorescence results, samples should undergo PFA fixation followed by Triton X-100 permeabilization before antibody application. This preparation method enables access to intracellular PKMYT1 while preserving cellular architecture. The visualization protocol typically involves antibody incubation at 4 μg/ml concentration, followed by appropriate fluorophore-conjugated secondary antibody detection .

How can I determine the binding kinetics of my PKMYT1 antibody?

The binding kinetics of PKMYT1 antibody can be determined using time-course ELISA methods under pseudo-first order kinetic conditions ([L] > > [mAb]). Multiple analytical approaches provide reliable on-rate constant (k+1) measurements:

Surface plasmon resonance provides an alternative method for direct measurement of association and dissociation rates in real-time .

What controls should be incorporated when using PKMYT1 antibody in experimental designs?

Robust experimental design requires multiple control strategies:

• Positive controls: Include cell lines with confirmed PKMYT1 expression (e.g., MCF7).

• Negative controls: Implement antibody controls (isotype-matched irrelevant antibody) and sample controls (PKMYT1 knockdown/knockout cells).

• Absorption controls: Pre-incubate antibody with immunizing peptide to confirm epitope specificity.

• Secondary antibody-only controls: Assess background fluorescence in immunostaining.

• Expression validation: Confirm PKMYT1 expression pattern using orthogonal methods (e.g., PCR, Western blot) alongside immunostaining.

These controls collectively ensure signal specificity and minimize false positive/negative results that could confound cell cycle regulation studies .

How can the specificity of PKMYT1 antibody be validated in experimental contexts?

Antibody specificity validation requires a multi-pronged approach:

• Western blot analysis: Confirm single band at expected molecular weight (~65 kDa for PKMYT1).

• Genetic manipulation: Demonstrate signal reduction/elimination in PKMYT1 knockdown/knockout samples.

• Immunoprecipitation-mass spectrometry: Identify pulled-down proteins to confirm target specificity.

• Peptide competition: Show signal reduction when antibody is pre-incubated with immunizing peptide.

• Cross-antibody validation: Compare results using antibodies targeting different PKMYT1 epitopes.

• Known expression pattern verification: Confirm expected subcellular localization and cell-cycle dependent expression patterns.

What methodological approaches can optimize PKMYT1 antibody performance in cell cycle studies?

For cell cycle studies, consider these specialized methodological approaches:

• Cell synchronization: Use double thymidine block or nocodazole treatment to enrich for specific cell cycle phases, then analyze PKMYT1 localization and expression.

• Phospho-specific detection: Combine PKMYT1 antibody with phospho-CDK1 (Thr14) antibodies to correlate PKMYT1 presence with its kinase activity.

• Live-cell imaging: Use fluorescently-tagged antibody fragments to track PKMYT1 dynamics throughout the cell cycle in real-time.

• Proximity ligation assay: Visualize PKMYT1 interactions with cyclins and CDK1 at different cell cycle stages.

• FACS-based analysis: Combine PKMYT1 immunostaining with DNA content analysis to correlate expression with precise cell cycle position.

These approaches provide mechanistic insights beyond simple protein detection, revealing functional relationships in cell cycle regulation .

How can differential PKMYT1 expression patterns be quantified across experimental conditions?

Quantitative analysis of PKMYT1 expression requires standardized methodologies:

• Image-based quantification:

  • Acquire z-stack images at consistent exposure settings across all samples

  • Perform background subtraction using secondary-only controls

  • Measure integrated density or mean fluorescence intensity within defined regions of interest

  • Normalize to cell number or nuclear area depending on experimental design

• Flow cytometry quantification:

  • Use median fluorescence intensity (MFI) as more robust than mean values

  • Apply fluorescence minus one (FMO) controls to set accurate gating

  • Calculate fold-change relative to control samples

  • Consider dual staining with cell cycle markers for phase-specific analysis

• Western blot quantification:

  • Use loading controls appropriate for subcellular fraction being analyzed

  • Apply linear range validation to ensure quantification within detector limits

  • Normalize band intensity to total protein rather than single housekeeping genes

  • Present data as fold-change with appropriate statistical analysis

What are the most common technical issues when using PKMYT1 antibodies?

Researchers frequently encounter several technical challenges when working with PKMYT1 antibodies:

• High background signal: Often results from insufficient blocking or excessive antibody concentration. Optimize blocking (3-5% BSA or serum from secondary antibody host species) and titrate primary antibody concentration.

• Weak or absent signal: May indicate low PKMYT1 expression, epitope masking, or antibody degradation. Verify PKMYT1 expression in your cell type, try alternative epitope retrieval methods, and ensure proper antibody storage conditions.

• Non-specific banding: Common with polyclonal antibodies like those against PKMYT1. Validate specificity through knockdown experiments and optimize washing conditions.

• Variable cell-to-cell staining: May reflect genuine biological variation in PKMYT1 expression throughout the cell cycle rather than technical issues.

• Poor reproducibility: Standardize all protocol steps including fixation time, permeabilization conditions, and antibody incubation periods .

How can I optimize PKMYT1 antibody performance in complex tissue samples?

When transitioning from cell lines to tissue samples, consider these methodological adjustments:

• Fixation optimization: Test multiple fixation methods (PFA, methanol, acetone) and durations to balance epitope preservation with tissue penetration.

• Enhanced permeabilization: Increase Triton X-100 concentration (0.2-0.5%) or try alternative permeabilization agents (saponin, digitonin) for dense tissues.

• Antigen retrieval: Implement heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) to unmask epitopes.

• Signal amplification: Employ tyramide signal amplification (TSA) or polymer-based detection systems to enhance sensitivity.

• Extended incubation: Increase primary antibody incubation time (overnight at 4°C) to improve tissue penetration.

• Background reduction: Add 0.1-0.3% Triton X-100 to antibody diluent to reduce non-specific binding in tissue sections .

How can PKMYT1 antibodies be used to investigate potential therapeutic applications?

PKMYT1 is gaining attention as a potential therapeutic target due to its role in cell cycle regulation. Antibody-based research approaches to explore this include:

• Target validation studies: Use PKMYT1 antibodies in immunohistochemistry to correlate expression levels with patient outcomes across various cancer types.

• Drug screening assays: Develop high-content screening platforms using PKMYT1 antibodies to identify compounds that modulate its expression or activity.

• Mechanism of action studies: Employ PKMYT1 antibodies in combination with phospho-specific antibodies to elucidate how candidate therapeutic compounds affect the PKMYT1-CDK1 regulatory axis.

• Resistance mechanism investigation: Apply PKMYT1 immunoprofiling to analyze samples before and after treatment to identify changes in expression or localization associated with therapeutic resistance.

• Combination therapy rational design: Use PKMYT1 antibodies to identify cell types and conditions where PKMYT1 inhibition might synergize with other therapeutic approaches .

What emerging technologies can enhance PKMYT1 antibody applications?

Several cutting-edge technologies are expanding the research applications of PKMYT1 antibodies:

• Super-resolution microscopy: Techniques like STORM and PALM can resolve PKMYT1 localization at nanometer scale, revealing previously undetectable spatial relationships with interaction partners.

• Single-cell proteomics: Methods combining antibody-based detection with single-cell isolation enable correlation of PKMYT1 expression with cellular phenotypes at unprecedented resolution.

• Spatial transcriptomics integration: Combining PKMYT1 immunostaining with in situ transcriptomics reveals relationships between protein expression and local transcriptional programs.

• AI-assisted image analysis: Machine learning algorithms can identify subtle patterns in PKMYT1 localization and expression that may escape human observation.

• Antibody engineering: Development of recombinant antibody fragments with enhanced tissue penetration and reduced background for improved PKMYT1 detection in complex samples .

How do post-translational modifications affect PKMYT1 antibody recognition?

Understanding how post-translational modifications (PTMs) impact PKMYT1 antibody binding is crucial for accurate experimental interpretation:

• Phosphorylation: PKMYT1 undergoes auto-phosphorylation and phosphorylation by upstream kinases, which may mask antibody epitopes or create conformation changes affecting recognition.

• Ubiquitination: Cell cycle-dependent ubiquitination of PKMYT1 may alter antibody accessibility to target epitopes.

• Glycosylation: Potential N-linked glycosylation could affect antibody binding, particularly for antibodies targeting the extracellular domain.

• Methodological approach: Researchers should validate antibody performance using both native and denatured PKMYT1 to assess PTM sensitivity.

• Validation strategy: Compare antibody binding before and after phosphatase treatment to determine if phosphorylation status affects detection .